aztreonam

Objective. To describe the phenotypic and genome characteristics of the phenomenon of aztreonam susceptibility changes in a clinical Pseudomonas aeruginosa isolate developing colistin resistance in an evolutionary experiment in vivo. Materials and Methods. A clinical P. aeruginosa isolate with a multiple drug resistance phenotype was examined using the spaciotemporal model of colistin resistance development under the increasing colistin concentration. During the 44-day experiment, isolates were selected from the frontal growing line; these isolates were subjected to antimicrobial susceptibility testing and genome sequencing.

One of the urgent problems of modern health care is the growing resistance of microorganisms to antibiotics, including carbapenems, which until recently were considered as the drugs of choice in the treatment of life-threatening infections. Enzymatic …

Objective. To compare the efficacy of ceftazidime-avibactam and aztreonam combination therapy with “standard” therapy in patients with hematological malignancies and sepsis, caused by carbapenemresistant K. pneumoniae. Materials and Methods. In this open, single center prospective-retrospective, cohort study, during 2019–2022, we analyze medical documentation of 81 hospitalized patients with hematologic malignancies and K. pneumoniae sepsis. K. pneumoniae was identified by MALDI-TOF mass-spectrometry; antimicrobial susceptibility testing was performed in accordance with current versions of EUCAST guidelines.